[Pfizer Inc.](https://www.pfizer.com)

May 6, 2026 (Submission deadline, full application)

Up to $80,000 for a one-year fellowship; funds cover salary and fellow benefits only

Supports U.S. institutions training healthcare professionals in clinical practice and research to improve diagnosis and management of transthyretin cardiac amyloidosis.

--- ## Description This competitive fellowship program is designed to advance the training of healthcare professionals—specifically cardiologists or heart failure advanced practice providers—in recognizing, diagnosing, and managing transthyretin cardiac amyloidosis (ATTR-CM). The program aims to address workforce gaps, promote expert mentorship, and foster independent research and education in this field. Awarded to U.S.-based academic institutions, the grant supports one-year fellowships that emphasize clinical practice, research, and education, with the overarching goal of deepening knowledge and improving outcomes for patients with ATTR cardiac amyloidosis. --- ## Due Dates - May 6, 2026: Submission deadline (full application) — applications must be submitted by 23:59 Eastern Standard Time --- ## Funding Amount - Up to $80,000 per awarded fellowship for a one-year term - Funding is to be used solely for the fellow’s salary and benefits (no overhead or indirect costs allowed) - Funding is awarded to the institution, not to individuals --- ## Eligibility - **Geographic Scope:** United States - **Eligible Applicants:** - Accredited, U.S.-based academic institutions with fellowship programs for cardiologists or heart failure advanced practice providers - Programs must have a strong focus on clinical practice, research, and education related to ATTR cardiac amyloidosis - Applicants must not include the name of the potential fellow(s) in application materials; the grant is institution-based - Programs must include independent research and strong mentorship; clinical training is optional - No aspect of the fellowship program or budget can benefit Pfizer’s business or assets - **Research Scope:** - Eligible: Observational studies, outcomes research, use of screening tools, and research focused on scientific understanding of disease - Not eligible: Studies involving pharmaceutical products, basic science, or fundamental research in animal/in vitro models - **Fellow Requirements:** - Must be a U.S. Worker (citizen, permanent resident, refugee, asylee) or hold an appropriate non-immigrant visa authorizing employment in the U.S. - Fellow time in the clinical setting funded by the grant cannot be billed as patient care --- ## Application Process - Applications must be submitted online via [CyberGrants: Pfizer Fellowship Portal](http://www.cybergrants.com/pfizer/GMGFellowship) - Complete all required sections of the online application and upload the proposal using the required template (10–15 pages, single-spaced, 12-point font, 1-inch margins) - In the application, select: - “Competitive Grant?”: Yes - Primary Area of Interest: CVM - ATTR-CM (Transthyretin Amyloid Cardiomyopathy) - FEL - Competitive Grant Program Name: 2026 RD US Cardiac Amyloidosis Fellowship - Required documents include a cover page, fellowship goals and objectives, methods, resources, challenges, institutional support letters, budget, and project timeline - Late applications will not be reviewed --- ## Additional Information - Award notifications are anticipated by June 19, 2026 - Projects are expected to start in September 2026 or later and last for one year - The fellowship must comply with the U.S. Physician Payments Sunshine Act and other transparency requirements; the selected fellow will be named in transparency reporting - No funds may be used for overhead or indirect costs - The program is competitive and uses an expert review panel for selection --- ## External Links - [Pfizer Fellowship RFP PDF](https://cdn.pfizer.com/pfizercom/2026-03/2026-RD-US-CardiacAmyloidosis-Fellowship.pdf?VersionId=Jao1B7KjDK5fp5eRfwssEo1LO1XDZhzV) - [Pfizer Inc.](https://www.pfizer.com) - [CyberGrants: Pfizer Fellowship Portal](http://www.cybergrants.com/pfizer/GMGFellowship) --- ## Contact Information | Contact | Email | Phone | Web | |-----------------------|-----------------------------------------------------|------------------|-------------------------------| | Grant Officer: Talita Honorato-Rzeszewicz | [Talita.honorato-rzeszewicz@pfizer.com](mailto:Talita.honorato-rzeszewicz@pfizer.com) | 1-800-879-3477 | [Pfizer Contact Page](https://www.pfizer.com/contact) | ---

Pfizer Fellowship Grant Request for Proposals: Transthyretin Cardiac Amyloidosis Fellowship

Sign in to see full grant listing